Ventrisana™ Active Ingredient Against Helicobacter pylori & Dyspepsia
Helicobacter pylori is a Gram-negative bacterium that most commonly colonizes the mucosa and endothelial cell layers of the gastrointestinal tract. It can cause dyspepsia, gastritis and plays important roles in peptic ulcer disease, gastric carcinoma, and gastric lymphoma. In the scientific literature it has also been associated with extra-gastric diseases including colorectal cancer, iron-deficit anemia, skin diseases and other pathologies.
Globally, Helicobacter pylori is a very common pathogen that is able to alter the physiology of infected carriers and to subvert the immune response, allowing it to persist for the life of the infected patient, if untreated. Infection by the oral route leads to dissemination and constant re-infection especially under conditions of poor hygiene.
To this day, gastric symptoms combined with diagnosed Helicobacter pylori infection will usually be treated with multiple antibiotics in parallel. This has very unpleasant side effects for the patient, such as nausea, sore oral mucosa, taste disorders and diarrhea. The increasing resistance rate of Helicobacter pylori to antibiotics leads to ever more complex and costly treatment regimen with complex resistance testing and limited eradication rates. There is a high unmet medical need for less complex therapeutic approaches with less risk of inducing antibiotic resistancies and microbiome dysregulation. Even more, prophylactic approaches against Helicobacter pylori promise a paradigm change in Helicobacter control.
In complex screening procedures a Lactobacillus reuteri strain was identified as a very potent innovative active ingredient for the treatment of Helicobacter pylori infection. The active ingredient has been brought to commercial maturity.
Ventrisana™ is highly selective, this means that it does not negatively interact with commensal bacteria of the gastrointestinal system. In contrast, antibiotic treatment can lead to massive dysbalance of the gastrointestinal microbiome, and also of the micobiome of the skin and on other body surfaces. Therefore, Ventrisana™ is the only truly selective therapeutic AND prophylactic approach towards controlling Helicobacter pylori infection.
The mechanism of action of Ventrisana™
The effect of the Ventrisana™ bacterium on Helicobacter pylori is fascinating. Within milliseconds, Helicobacter pylori firmly adheres to the cell walls of inactivated Ventrisana™ bacteria and co-aggregates when brought together in a liquid environment. Lumps of these co-aggregates can be observed under the electron microscope. These co-aggregates are transported into the intestine with the normal flow of food and rendered harmless.
Since the mechanism of action is based on the bacterial cell wall, we do not need to introduce living bacteria in products. Ventrisana™ contains only the bacterial envelopes and does not impose any risks of overcolonization or genetic transfer with the gastrointestinal microbiome.
Clinically, long-term reductions of gastrointestinal Helicobacter pylori load for more than six months and improvement of dyspeptic symptoms could be observed in studies with the active ingredient.
Belano medical AG develops prophylactic and therapeutic applications against Helicobacter pylori which are based on the active ingredient Ventrisana™.
Ventrisana™ in an oral formulation is currently under development as a substance-based medical device in the EU. As soon as the confomity assessment procedure has been successfully finalized you will be able to purchase Ventrisana™.
Ventrisana™ will be available in an oral formulation as a medical device as soon as the product conformity assessment procedure has been successfully finalized. The product will come packed in blisters.
We are looking for experienced distributors interested to take up the brand Ventrisana™ or under their own brand label into their portfolio for distribution within the EU and internationally.
Ventrisana™ is patent protected.